Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asundexian - Bayer

Next Previous
Drug Profile

Asundexian - Bayer

Alternative Names: BAY-2433334

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Amides; Anticoagulants; Antithrombotics; Chlorobenzenes; Ethers; Fluorobenzenes; Pyridines; Small molecules; Triazoles; Vascular disorder therapies
  • Mechanism of Action Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Stroke; Thromboembolism

Most Recent Events

  • 23 Nov 2025 Efficacy and adverse events data from a phase-III OCEANIC-STROKE trial in Stroke (prevention) released by Bayer
  • 23 Oct 2025 Bayer completes a phase III trial in Stroke (Prevention) in USA, Argentina, Australia, Austria, Belgium, Brazil, Bulgari, Canada, China, Czech Republic, France, Germany, Greece, India, Israel, Italy, Kazakhstan, South Korea, Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, United kingdom and Finland (PO) (NCT05686070)
  • 29 Oct 2024 Bayer completes a phase I trial (In volunteers) in Germany (PO) (CTIS2023-509447-28-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top